First Header Logo Second Header Logo

Caio Max Rocha Lima

Concepts (292)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pancreatic Neoplasms
33
2016
142
6.570
Why?
Antineoplastic Combined Chemotherapy Protocols
42
2017
462
6.320
Why?
Deoxycytidine
28
2014
68
3.550
Why?
Camptothecin
19
2014
53
2.970
Why?
Antineoplastic Agents
18
2016
611
2.070
Why?
Colorectal Neoplasms
13
2015
222
2.070
Why?
Lung Neoplasms
20
2015
409
1.780
Why?
Adenocarcinoma
12
2015
315
1.700
Why?
Neoplasms
12
2016
695
1.420
Why?
Taxoids
11
2017
59
1.310
Why?
Fluorouracil
12
2014
82
1.280
Why?
Antimetabolites, Antineoplastic
8
2010
49
1.230
Why?
Organoplatinum Compounds
8
2014
47
1.130
Why?
Carcinoma, Small Cell
8
2012
25
1.120
Why?
Carcinoma, Non-Small-Cell Lung
10
2006
101
1.110
Why?
Middle Aged
57
2017
11949
0.960
Why?
Antibodies, Monoclonal
10
2013
250
0.930
Why?
Aged
52
2017
10398
0.920
Why?
Humans
87
2017
32297
0.910
Why?
Paclitaxel
5
2013
67
0.890
Why?
Adult
44
2017
9467
0.810
Why?
Treatment Outcome
27
2017
3358
0.770
Why?
Male
56
2017
19488
0.740
Why?
Neoadjuvant Therapy
7
2012
67
0.720
Why?
Salvage Therapy
4
2011
134
0.720
Why?
Colonic Neoplasms
3
2010
73
0.710
Why?
Female
56
2017
20126
0.700
Why?
Chemotherapy, Adjuvant
8
2015
191
0.700
Why?
Neoplasm Metastasis
7
2014
222
0.700
Why?
Disease-Free Survival
11
2017
320
0.660
Why?
Gastrointestinal Stromal Tumors
5
2010
12
0.660
Why?
Antineoplastic Agents, Phytogenic
4
2005
38
0.660
Why?
Drug Administration Schedule
11
2016
279
0.630
Why?
Survival Analysis
11
2014
491
0.610
Why?
Cancer Vaccines
2
2014
24
0.590
Why?
Leucovorin
3
2012
25
0.590
Why?
Indoles
4
2016
60
0.580
Why?
Pyrroles
4
2016
57
0.580
Why?
Maximum Tolerated Dose
10
2014
60
0.570
Why?
Carcinoma, Pancreatic Ductal
2
2016
21
0.560
Why?
Aged, 80 and over
24
2017
4050
0.560
Why?
Neoplasm Recurrence, Local
7
2017
370
0.560
Why?
Carcinoma
3
2012
93
0.560
Why?
Neoplasm Staging
11
2014
459
0.550
Why?
Palliative Care
2
2010
54
0.540
Why?
Protein Kinase Inhibitors
3
2012
85
0.520
Why?
Endosonography
4
2011
56
0.520
Why?
Topotecan
4
2009
17
0.510
Why?
Angiogenesis Inhibitors
3
2016
36
0.500
Why?
Gastrins
1
2014
4
0.490
Why?
Stomach Neoplasms
3
2014
84
0.470
Why?
Esophageal Neoplasms
3
2011
35
0.460
Why?
Survival Rate
15
2012
894
0.450
Why?
Albumins
1
2013
46
0.440
Why?
Cell Cycle
1
2012
78
0.420
Why?
Antimitotic Agents
1
2012
2
0.410
Why?
Rectal Neoplasms
2
2009
18
0.410
Why?
Oligopeptides
1
2012
51
0.410
Why?
Clinical Trials as Topic
6
2008
316
0.400
Why?
Biopsy, Fine-Needle
4
2011
53
0.390
Why?
Piperidines
2
2012
125
0.390
Why?
Biliary Tract Neoplasms
2
2017
10
0.380
Why?
Carcinoma, Squamous Cell
1
2012
154
0.380
Why?
Cytoskeletal Proteins
1
2010
15
0.380
Why?
Infusions, Intravenous
5
2014
100
0.370
Why?
Drug Therapy
1
2010
16
0.360
Why?
Biopsy, Needle
2
2008
98
0.350
Why?
DNA Methylation
1
2010
142
0.340
Why?
Prognosis
9
2015
1523
0.330
Why?
Etoposide
3
2007
34
0.330
Why?
CA-19-9 Antigen
2
2013
6
0.320
Why?
Receptors, Vascular Endothelial Growth Factor
1
2008
21
0.310
Why?
Emphysematous Cholecystitis
1
2007
1
0.300
Why?
Drug Delivery Systems
1
2008
101
0.290
Why?
Quinazolines
4
2008
38
0.290
Why?
Carcinoma, Neuroendocrine
1
2007
13
0.290
Why?
Ultrasonography, Interventional
2
2011
53
0.290
Why?
Mediastinal Neoplasms
1
2006
13
0.280
Why?
Drug Resistance, Neoplasm
3
2012
105
0.280
Why?
Ablation Techniques
2
2016
26
0.260
Why?
Lymph Nodes
1
2006
106
0.260
Why?
Randomized Controlled Trials as Topic
8
2015
511
0.260
Why?
Electroporation
2
2016
14
0.250
Why?
Combined Modality Therapy
7
2010
567
0.250
Why?
Retrospective Studies
11
2016
3514
0.240
Why?
Disease Progression
5
2010
618
0.240
Why?
Coronary Vasospasm
1
2004
4
0.240
Why?
Diarrhea
3
2014
60
0.230
Why?
Hospitals, General
1
2013
4
0.230
Why?
Cancer Care Facilities
1
2013
10
0.230
Why?
Follow-Up Studies
7
2014
2296
0.220
Why?
Drug Synergism
3
2014
71
0.220
Why?
Liver Neoplasms
3
2014
159
0.220
Why?
Carboplatin
5
2007
48
0.220
Why?
Genetic Markers
1
2002
125
0.210
Why?
Vomiting
2
2014
25
0.170
Why?
Tomography, X-Ray Computed
3
2016
920
0.170
Why?
Nausea
2
2014
54
0.170
Why?
Pancreatic Diseases
2
2010
18
0.170
Why?
Protein-Tyrosine Kinases
2
2010
40
0.170
Why?
Gastrointestinal Neoplasms
2
2011
33
0.170
Why?
Clinical Trials, Phase III as Topic
4
2002
28
0.160
Why?
European Continental Ancestry Group
2
2014
1180
0.160
Why?
Piperazines
2
2010
60
0.160
Why?
Pyrimidines
2
2010
65
0.150
Why?
Endothelins
1
2017
4
0.150
Why?
Pyridines
2
2008
81
0.150
Why?
Brain Neoplasms
1
2003
638
0.150
Why?
Radiography, Interventional
1
2016
37
0.140
Why?
Epothilones
1
2016
3
0.140
Why?
Tubulin Modulators
1
2016
10
0.140
Why?
Young Adult
4
2014
2626
0.140
Why?
Pancreatectomy
2
2012
32
0.130
Why?
African Americans
2
2014
1443
0.130
Why?
Clinical Trials, Phase II as Topic
4
2006
17
0.130
Why?
Splenic Artery
1
2015
11
0.130
Why?
Thrombocytopenia
1
2015
32
0.130
Why?
Neutropenia
1
2014
30
0.120
Why?
Breast Neoplasms
3
2012
759
0.120
Why?
Electrochemotherapy
1
2014
3
0.120
Why?
Injections, Intramuscular
1
2014
43
0.120
Why?
Embolization, Therapeutic
1
2015
88
0.120
Why?
Sensitivity and Specificity
4
2011
600
0.120
Why?
Time Factors
4
2016
2181
0.120
Why?
Peptide Fragments
1
2017
422
0.120
Why?
Perception
1
2014
98
0.120
Why?
Pancreas
2
2011
104
0.110
Why?
Immunohistochemistry
2
2012
545
0.110
Why?
Quality of Life
3
2004
915
0.110
Why?
Receptor, erbB-2
1
2014
65
0.110
Why?
Arsenic
1
2013
4
0.110
Why?
Hematologic Diseases
2
2004
24
0.110
Why?
Proto-Oncogene Proteins c-kit
2
2010
24
0.110
Why?
Trisaccharides
1
2012
1
0.110
Why?
Deoxyglucose
1
2012
16
0.110
Why?
Immunotherapy, Active
1
2012
6
0.110
Why?
Cyclin-Dependent Kinases
1
2012
9
0.110
Why?
Attitude to Health
1
2014
167
0.110
Why?
Pancreaticoduodenectomy
1
2012
23
0.110
Why?
Prospective Studies
7
2014
2274
0.110
Why?
Benzamides
2
2010
53
0.110
Why?
Drug Design
1
2012
47
0.110
Why?
Clinical Trials, Phase I as Topic
3
2004
14
0.110
Why?
Environmental Exposure
1
2013
92
0.100
Why?
Catheter Ablation
1
2012
67
0.100
Why?
Adolescent
4
2014
3571
0.100
Why?
Triazines
1
2011
3
0.100
Why?
Algorithms
2
2012
497
0.100
Why?
Boronic Acids
2
2008
8
0.100
Why?
Alanine
1
2011
27
0.100
Why?
Pyrazines
2
2008
14
0.100
Why?
Celiac Plexus
1
2011
3
0.100
Why?
Cell Line, Tumor
2
2010
736
0.100
Why?
Diagnosis, Differential
3
2010
525
0.100
Why?
Family
1
2011
115
0.100
Why?
Metalloproteases
1
2010
4
0.100
Why?
Diagnostic Imaging
2
2008
93
0.090
Why?
CARD Signaling Adaptor Proteins
1
2010
5
0.090
Why?
Cyclooxygenase 2 Inhibitors
1
2010
15
0.090
Why?
Abdominal Pain
1
2011
45
0.090
Why?
Azacitidine
1
2010
28
0.090
Why?
Gene Silencing
1
2010
49
0.090
Why?
Proto-Oncogene Proteins c-akt
1
2010
70
0.090
Why?
Mutation
2
2010
503
0.090
Why?
Transfection
1
2010
202
0.090
Why?
Vascular Endothelial Growth Factor A
1
2010
110
0.090
Why?
Caregivers
1
2011
112
0.090
Why?
Biliary Tract Diseases
1
2010
12
0.090
Why?
Cisplatin
3
2011
77
0.090
Why?
Promoter Regions, Genetic
1
2010
213
0.090
Why?
Cholangiopancreatography, Endoscopic Retrograde
1
2010
33
0.090
Why?
Radiation Tolerance
1
2009
24
0.090
Why?
Proteins
1
2010
150
0.090
Why?
Models, Genetic
1
2009
94
0.090
Why?
Lymphatic Metastasis
2
2007
172
0.080
Why?
Benzenesulfonates
1
2008
3
0.080
Why?
Phenylurea Compounds
1
2008
10
0.080
Why?
Niacinamide
1
2008
8
0.080
Why?
Depression
1
2011
436
0.080
Why?
Gene Expression
1
2009
345
0.080
Why?
DNA Topoisomerases, Type I
2
2006
9
0.080
Why?
Endoscopy
1
2008
57
0.080
Why?
Head and Neck Neoplasms
1
2009
129
0.080
Why?
Patient Care Team
1
2008
131
0.080
Why?
Administration, Oral
2
2007
185
0.080
Why?
Cholecystostomy
1
2007
1
0.070
Why?
Hyperbilirubinemia
1
2007
2
0.070
Why?
Leukocytosis
1
2007
8
0.070
Why?
Phosphorylcholine
1
2007
5
0.070
Why?
Probability
1
2007
160
0.070
Why?
Radiography
2
2012
377
0.070
Why?
Risk Factors
2
2014
3876
0.070
Why?
Proportional Hazards Models
3
2016
759
0.070
Why?
Acute Disease
1
2007
255
0.070
Why?
Feasibility Studies
1
2007
294
0.070
Why?
Sarcoma
1
2007
71
0.070
Why?
Equipment Design
1
2006
172
0.070
Why?
Models, Statistical
1
2006
176
0.060
Why?
Alkyl and Aryl Transferases
1
2004
2
0.060
Why?
Thalidomide
1
2005
31
0.060
Why?
Quinolones
1
2004
7
0.060
Why?
Enterocolitis, Neutropenic
1
2004
1
0.060
Why?
Electrocardiography
2
2012
635
0.060
Why?
Aniline Compounds
1
2014
27
0.060
Why?
Dose-Response Relationship, Drug
4
2010
675
0.060
Why?
Anti-Bacterial Agents
1
2007
309
0.060
Why?
Patient Selection
2
2007
289
0.060
Why?
Proto-Oncogene Proteins c-bcl-2
1
2014
40
0.060
Why?
Imidazoles
1
2004
97
0.060
Why?
Lymphocytes
1
2004
58
0.060
Why?
Signal Transduction
1
2008
701
0.060
Why?
Sulfonamides
1
2014
67
0.060
Why?
Enzyme Inhibitors
1
2004
176
0.060
Why?
Hospitals, Voluntary
1
2013
2
0.060
Why?
Epidermal Growth Factor
1
2003
27
0.060
Why?
Blood-Brain Barrier
1
2003
50
0.060
Why?
SEER Program
3
2007
36
0.050
Why?
Poverty
1
2013
111
0.050
Why?
Survival
1
2002
13
0.050
Why?
Neoplasms, Unknown Primary
1
2002
6
0.050
Why?
Safety
1
2002
78
0.050
Why?
Age Distribution
1
2002
210
0.050
Why?
Lymphoma, Non-Hodgkin
1
2001
22
0.050
Why?
Stress, Psychological
2
2014
218
0.050
Why?
Granulocyte Colony-Stimulating Factor
1
2001
24
0.050
Why?
Hematologic Neoplasms
1
2001
34
0.050
Why?
Longitudinal Studies
2
2014
786
0.050
Why?
Multicenter Studies as Topic
1
2000
102
0.050
Why?
Florida
2
2013
37
0.040
Why?
Area Under Curve
2
2010
95
0.040
Why?
Tumor Burden
1
2016
61
0.040
Why?
Reproducibility of Results
2
2010
779
0.040
Why?
Incidence
2
2013
1207
0.030
Why?
Neovascularization, Pathologic
1
2016
82
0.030
Why?
Georgia
1
2014
14
0.030
Why?
Registries
2
2007
300
0.030
Why?
Family Relations
1
2014
23
0.030
Why?
Epirubicin
1
2014
1
0.030
Why?
Water Supply
1
2013
10
0.030
Why?
Positron-Emission Tomography
1
2014
190
0.030
Why?
Antigens, Neoplasm
1
2013
46
0.030
Why?
Cluster Analysis
1
2013
131
0.030
Why?
Receptor, IGF Type 1
1
2012
7
0.030
Why?
Placebos
1
2012
66
0.030
Why?
Rare Diseases
1
2012
20
0.030
Why?
Neoplasm Proteins
1
2013
149
0.030
Why?
Esophagogastric Junction
1
2011
7
0.030
Why?
Aneuploidy
1
2011
10
0.020
Why?
Chromosomes, Human, Pair 17
1
2011
13
0.020
Why?
Chromosomes, Human, Pair 9
1
2011
16
0.020
Why?
Chromosomes, Human, Pair 7
1
2011
15
0.020
Why?
In Situ Hybridization, Fluorescence
1
2011
41
0.020
Why?
Sequence Deletion
1
2011
40
0.020
Why?
Chromosomes, Human, Pair 3
1
2011
28
0.020
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2011
23
0.020
Why?
Tissue Distribution
1
2011
62
0.020
Why?
Autonomic Nerve Block
1
2011
10
0.020
Why?
Analgesia
1
2011
32
0.020
Why?
Logistic Models
1
2013
788
0.020
Why?
Drug Therapy, Combination
1
2011
301
0.020
Why?
Social Support
1
2011
180
0.020
Why?
Antigens, Tumor-Associated, Carbohydrate
1
2010
3
0.020
Why?
Half-Life
1
2010
22
0.020
Why?
Biliary Tract
1
2010
7
0.020
Why?
Blood Glucose
1
2012
496
0.020
Why?
Pain Measurement
1
2011
370
0.020
Why?
Oligonucleotide Array Sequence Analysis
1
2009
163
0.020
Why?
Sample Size
1
2008
39
0.020
Why?
Linear Models
1
2009
454
0.020
Why?
United States
2
2007
3983
0.020
Why?
Muscle Neoplasms
1
2007
9
0.020
Why?
Endoscopy, Gastrointestinal
1
2007
25
0.020
Why?
Muscle, Smooth
1
2007
74
0.020
Why?
Antiemetics
1
2007
6
0.020
Why?
DNA Topoisomerases, Type II
1
2006
4
0.020
Why?
Bone Neoplasms
1
2007
112
0.020
Why?
Population Surveillance
1
2007
124
0.020
Why?
Case-Control Studies
1
2008
911
0.020
Why?
Farnesyltranstransferase
1
2004
2
0.020
Why?
Inhibitory Concentration 50
1
2004
23
0.020
Why?
Models, Chemical
1
2004
34
0.020
Why?
Multivariate Analysis
1
2007
696
0.020
Why?
Leukocytes, Mononuclear
1
2004
57
0.020
Why?
Flavonoids
1
2004
18
0.020
Why?
Fatal Outcome
1
2004
86
0.010
Why?
Peritoneal Neoplasms
1
2007
263
0.010
Why?
Severity of Illness Index
1
2007
926
0.010
Why?
Cohort Studies
1
2007
1832
0.010
Why?
Vinblastine
1
2000
6
0.010
Why?
Remission Induction
1
2000
84
0.010
Why?
Child
1
2007
2472
0.010
Why?
Tumor Cells, Cultured
1
1999
171
0.010
Why?
Rocha Lima's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (292)
Explore
_
Similar People (48)
Explore
_
Same Department Expand Description
Explore
_